HEALTH ALERT! If you have any of the following, please call our office before coming in for your appointment: Fever AND cough; Fever OR cough and recent travel (domestic or international to any destination); Recent international travel to areas impacted by the Coronavirus (2019-nCoV) within the last 14 days; OR close contact with someone who has traveled outside the US or been exposed to the Coronavirus. Read more

Clinical Trials & Research

Search for Clinical Trials

Search Trials

NOW OPEN! USOR 19247 A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatments in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant (54767414MMY3021)

Disease Types: Multiple Myeloma
Available at: Arlington Heights, Niles


NOW OPEN - HER2+ Breast Trial USOR 19054: A Randomized, Double-Blind, Phase 3 Study of Tucatinib or Placebo in Combination with Ado-Trastuzumab Emtansine (T-DM1) for Subjects with Unresectable, Locally-Advanced, or Metastatic HER2+ Breast Cancer. (HER2CLIMB-02)(SGNTUC-016)

Disease Types: Breast
Available at: Arlington Heights, Niles


NOW OPEN! USOR 19221: A Randomized, Multicentre, Double-Blind, Placebo-Controlled, Phase III Study of First-Line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer. (DUO-E) D9311C00001; GOG-3041; ENGOT-EN10

Disease Types: Endometrial
Available at: Arlington Heights, Niles


NOW OPEN! USOR 19205 ULTRA-V: A Phase 2 Study to Assess the Efficacy and Safety of Ublituximab in Combination with Umbralisib and Venetoclax (U2-V) in Subjects with Chronic Lymphocytic Leukemia (CLL)(U2-VEN-207)

Disease Types: Leukemia
Available at: Arlington Heights, Niles


USOR 19018: A Randomized, Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE) Mirati 516-005

Disease Types: Lung - Non-Small Cell Lung
Available at: Arlington Heights, Niles


USOR 19192 A Phase III, Randomized, Double-Blinded, Placebo-Controlled Study of Tiragolumab, An Anti-Tigit Antibody, In Combination with Atezolizumab, Compared with Placebo In Combination With Atezolizumab, In Patients With Previously Untreated, Locally Advanced, Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer. (GO41717)

Disease Types: Lung - Non-Small Cell Lung
Available at: Arlington Heights, Niles


USOR 19079 A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)(INCB54828-207)

Disease Types: Solid Tumor
Available at: Arlington Heights, Niles


USOR 19200 A Randomized, Open-Label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression. (IMGN853-0416)(MIRASOL)

Disease Types: Gynecological/Ovarian
Available at: Arlington Heights, Niles


USOR 19094: QBGJ398-302: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations. (PROOF302)

Disease Types: Bladder, Urothelial
Available at: Arlington Heights


USOR 18264: A Phase 3, Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations. The PROOF Trial (QBGJ398-301)

Disease Types: Cholangiocarcinoma
Available at: Arlington Heights, Niles


USOR 18155 A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL.) (BGB-3111-305)

Disease Types: Leukemia
Available at: Arlington Heights, Niles


USOR 17160 / PANOVA-3: Pivotal, Randomized, Open-Label Study of Tumor Testing Fields (TTFields, 150kHz) concomitant with Gemcitabine and Nab-Paclitaxel for Front-Line Treatment of Locally-Advanced Pancreatic Adenocarcinoma (EF-27)

Disease Types: Pancreas
Available at: Niles, Arlington Heights


AGIOS AG120-C-009 A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects 18 Years of Age and Older, with Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation.

Disease Types: Leukemia
Available at: Niles, Arlington Heights


USOR 16065 Relapsed/Refractory - A Phase 2b, Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 and TGR-1202 Alone in Patients with Previously Treated Diffuse Large B-Cell Lymphoma. (UTX-TGR-205)

Disease Types: Lymphoma
Available at: Niles, Arlington Heights


USOR 16100 Hodgkins Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices. (CA20965)

Disease Types: Lymphoma
Available at: Niles, Arlington Heights


USOR 08160 PNH Registry: Primary Objective of the Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry will Collect Data to Evaluate Safety Data Specific to the Use of Solaris and to Characterize the Progression of PNH as well as Clinical Outcomes, Mortality and Morbidity in Solaris and Non-Solaris Treated Patients. Secondary Objective is Raising PNH Awareness in the Medical Community and Patient/Potential Patient Population. (M07-001)

Disease Types: PNH
Available at: Niles, Arlington Heights